Parkinson's Disease and development of levodopa induced motor complications: Influence of baseline features and first medical approach
- PMID: 32258564
- PMCID: PMC6806991
- DOI: 10.1016/j.pbj.2016.08.001
Parkinson's Disease and development of levodopa induced motor complications: Influence of baseline features and first medical approach
Abstract
Background: The introduction of levodopa in clinical practice represents a hallmark in the treatment of the neurodegenerative disease, Parkinson's Disease. However, levodopa induced motor complications, namely dyskinesias and motor fluctuations, develop in the majority of Parkinson's Disease patients.
Objective: to identify which Parkinson's Disease's, patient's and therapeutics' initial features are more associated with dyskinesias or motor fluctuations development.
Methods: Patients with diagnosed Parkinson's Disease attending neurology outpatient clinic at Centro Hospitalar São João were selected. For this observational study, data was retrospectively collected from patient's clinical records. A survival analysis model with univariate and multivariate regression analysis was used.
Results: 87 patients with a mean of 72 ± 9.7 years were included. After a median follow-up of 6 (range 1-17) years, 35.6% patients developed dyskinesias; and with a median of 5 (range 1-16) years, 32.2% developed motor fluctuations. After multivariate analysis, the akinesia/rigidity subtype was found to have a higher risk of dyskinesias and motor fluctuations development. Age of onset ≤50 years was associated with motor fluctuations development.
Conclusion: In conclusion, our results suggest that Parkinson's Disease patients' initial characteristics, such as subtype or age of onset, are independently associated with the development of motor complications.
Keywords: Dyskinesia; Levodopa; Motor Fluctuations; Parkinson's Disease.
Copyright 2016 PBJ-Associação Porto Biomedical/Porto Biomedical Society.
Conflict of interest statement
This study was not funded and conflicts of interest are inexistent.
Figures
References
-
- Raudino F. The Parkinson disease before James Parkinson. Neurol Sci. 2012;33:945-948. PubMed PMID: 22005945. - PubMed
-
- Dexter DT, Jenner P. Parkinson disease: from pathology to molecular disease mechanisms. Free Radic Biol Med. 2013;62:132-144. PubMed PMID: 23380027. - PubMed
-
- Moore RY. Organization of midbrain dopamine systems and the pathophysiology of Parkinson's disease. Parkinsonism Relat Disord. 2003;9(Suppl. 2):S65-S71, PubMed PMID: 12915070. Epub 2003/08/14.eng. - PubMed
-
- Litvan I, Bhatia KP, Burn DJ, Goetz CG, Lang AE, McKeith I, et al. Movement Disorders Society Scientific Issues Committee report: SIC Task Force appraisal of clinical diagnostic criteria for Parkinsonian disorders. Mov Disord. 2003;18:467-486. PubMed PMID: 12722160. Epub 2003/05/02.eng. - PubMed
-
- Goetz CG, Poewe W, Rascol O, Sampaio C, Stebbins GT, Counsell C, et al. Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations. Mov Disord. 2004;19:1020-1028. PubMed PMID: 15372591. - PubMed
LinkOut - more resources
Full Text Sources